Pharmaceutical spend is still growing at rates greater than overall healthcare spend. These continually
increasing costs are putting pharmacy spending under the spotlight to demonstrate a positive cost benefit
analysis. Pharmaceutical companies are some of the major sponsors of disease management programs.
Many disease management programs use pharmaceutical products as a core component of program
delivery or member identification and stratification.
What kind of impact is Part D having on disease management for the senior population? Is some of the
negative press on "big pharma" impacting their presence in the disease management market? Come
hear speakers talk about the ongoing role "big pharma" will have in the future and the role pharmacy
product usage plays in today's and future disease management programs.